Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01570855 · ClinicalTrials.gov registry record
Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
A clinical trial, sponsored by Marshall University.
- Completed
- Registry status
- 45
- Enrollment target
NCT01570855: Completed study, sponsored by Marshall University.
NCT01570855 is a clinical trial that has completed, run by Marshall University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01570855 has completed, sponsored by Marshall University.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.
Primary Outcome
Tumor response will be evaluated (progression/regression) by CT scan at 3 months from therapy start. Clinical response to chemotherapy of lung cancer tumor cells versus lung cancer stem cells to standard of care chemo drugs will be evaluated and correlated to predicted drug by ex vivo assay.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-12 |
What the finished NCT01570855 record still lists
NCT01570855 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01570855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01570855 about?
NCT01570855 is a clinical study titled "Chemotherapy Resistance and Sensitivity Testing in Lung Tumors". The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients tre...
What is the current status of trial NCT01570855?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2011-10. Estimated completion is 2015-12.
Who is sponsoring clinical trial NCT01570855?
This trial is sponsored by Marshall University, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia